These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32926148)

  • 21. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
    Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
    Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
    Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
    Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease.
    Tible M; Sandelius Å; Höglund K; Brinkmalm A; Cognat E; Dumurgier J; Zetterberg H; Hugon J; Paquet C; Blennow K
    Neurology; 2020 Aug; 95(8):e953-e961. PubMed ID: 32586895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease.
    Majbour NK; Chiasserini D; Vaikath NN; Eusebi P; Tokuda T; van de Berg W; Parnetti L; Calabresi P; El-Agnaf OM
    Sci Rep; 2017 Jan; 7():40263. PubMed ID: 28071698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
    Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
    Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
    Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
    J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.
    Thorsell A; Bjerke M; Gobom J; Brunhage E; Vanmechelen E; Andreasen N; Hansson O; Minthon L; Zetterberg H; Blennow K
    Brain Res; 2010 Nov; 1362():13-22. PubMed ID: 20875798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
    Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
    J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders.
    Li JQ; Bi YL; Shen XN; Wang HF; Xu W; Tan CC; Dong Q; Wang YJ; Tan L; Yu JT;
    Transl Neurodegener; 2020 Nov; 9(1):41. PubMed ID: 33228804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays.
    Öhrfelt A; Dumurgier J; Zetterberg H; Vrillon A; Ashton NJ; Kvartsberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
    Alzheimers Res Ther; 2020 Dec; 12(1):168. PubMed ID: 33353563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased CSF neurogranin concentration is specific to Alzheimer disease.
    Wellington H; Paterson RW; Portelius E; Törnqvist U; Magdalinou N; Fox NC; Blennow K; Schott JM; Zetterberg H
    Neurology; 2016 Mar; 86(9):829-35. PubMed ID: 26826204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
    Hall S; Janelidze S; Zetterberg H; Brix B; Mattsson N; Surova Y; Blennow K; Hansson O
    Mov Disord; 2020 Mar; 35(3):513-518. PubMed ID: 31837067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
    Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
    Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Roveta F; Cermelli A; Boschi S; Ferrandes F; Grassini A; Marcinnò A; Spina M; Rubino E; Borsello T; Vercelli A; Rainero I
    J Alzheimers Dis; 2022; 90(4):1381-1393. PubMed ID: 36278349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.